Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

206 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Targeting, toxicity, and efficacy of 2-step, pretargeted radioimmunotherapy using a chimeric bispecific antibody and 131I-labeled bivalent hapten in a phase I optimization clinical trial.
Kraeber-Bodéré F, Rousseau C, Bodet-Milin C, Ferrer L, Faivre-Chauvet A, Campion L, Vuillez JP, Devillers A, Chang CH, Goldenberg DM, Chatal JF, Barbet J. Kraeber-Bodéré F, et al. Among authors: chatal jf. J Nucl Med. 2006 Feb;47(2):247-55. J Nucl Med. 2006. PMID: 16455630 Free article. Clinical Trial.
Brown fat in breast cancer patients: analysis of serial (18)F-FDG PET/CT scans.
Rousseau C, Bourbouloux E, Campion L, Fleury N, Bridji B, Chatal JF, Resche I, Campone M. Rousseau C, et al. Among authors: chatal jf. Eur J Nucl Med Mol Imaging. 2006 Jul;33(7):785-91. doi: 10.1007/s00259-006-0066-x. Epub 2006 Apr 5. Eur J Nucl Med Mol Imaging. 2006. PMID: 16596378 Clinical Trial.
Phase II trial of anticarcinoembryonic antigen pretargeted radioimmunotherapy in progressive metastatic medullary thyroid carcinoma: biomarker response and survival improvement.
Salaun PY, Campion L, Bournaud C, Faivre-Chauvet A, Vuillez JP, Taieb D, Ansquer C, Rousseau C, Borson-Chazot F, Bardet S, Oudoux A, Cariou B, Mirallié E, Chang CH, Sharkey RM, Goldenberg DM, Chatal JF, Barbet J, Kraeber-Bodéré F. Salaun PY, et al. Among authors: chatal jf. J Nucl Med. 2012 Aug;53(8):1185-92. doi: 10.2967/jnumed.111.101865. Epub 2012 Jun 28. J Nucl Med. 2012. PMID: 22743249 Free article. Clinical Trial.
¹⁸F-FDG PET predicts survival after pretargeted radioimmunotherapy in patients with progressive metastatic medullary thyroid carcinoma.
Salaun PY, Campion L, Ansquer C, Frampas E, Mathieu C, Robin P, Bournaud C, Vuillez JP, Taieb D, Rousseau C, Drui D, Mirallié E, Borson-Chazot F, Goldenberg DM, Chatal JF, Barbet J, Kraeber-Bodéré F. Salaun PY, et al. Among authors: chatal jf. Eur J Nucl Med Mol Imaging. 2014 Aug;41(8):1501-10. doi: 10.1007/s00259-014-2772-0. Epub 2014 May 8. Eur J Nucl Med Mol Imaging. 2014. PMID: 24806110 Clinical Trial.
Alphatherapy, the new impetus to targeted radionuclide therapy?
Chatal JF, Kraeber-Bodéré F, Chérel M, Haddad F. Chatal JF, et al. Eur J Nucl Med Mol Imaging. 2018 Jul;45(8):1362-1363. doi: 10.1007/s00259-018-4026-z. Eur J Nucl Med Mol Imaging. 2018. PMID: 29696441 No abstract available.
206 results